In this pathway, TCF4, also called TCF7L2, forms a complex with beta-catenin, and the beta-catenin–TCF4 transcription factor complex binds preferentially to the cancer risk-associated rs6983267 (G) allele in vivo and in vitro leading to a two-fold change in c-MYC expression [30]. The gene discussed is TCF4; the disease is cancer.